This study is looking at a new way to treat solid tumors using a special type of immune cell called RAPA-201. These cells are designed to help the body fight cancer more effectively, especially in patients whose tumors have not responded to other treatments. The goal is to see how well these cells work in helping patients with advanced solid tumors that have not improved after previous therapies.
The trial is identified as NCT05144698. It is a Phase I/II study, meaning it is looking at both the safety and effectiveness of the treatment. The trial is regulated by the FDA, and it aims to include about 37 participants.
Who can join
This trial is open to adults aged 18 and older, including both men and women. Participants should have solid tumors that have worsened after at least one previous treatment. They must also have had treatment using a specific type of therapy that blocks certain cancer pathways. The trial team will check to confirm eligibility for each interested person.
Conditions
Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will receive RAPA-201 cells, which are specially prepared immune cells, at a set dose during the study. They will also receive a chemotherapy treatment before the RAPA-201 therapy. After this therapy, participants will continue with another medication called pembrolizumab for up to a year. Everyone in the study will receive the treatment, as there are no different groups in this trial.
Where
This trial is running at 1 location in the United States. It is currently recruiting.